Raydiant Oximetry

Focus: Raydiant Oximetry is a Series B biotech focused on fetal monitoring devices, specifically developing non-invasive oximetry and sensing systems to detect fetal hypoxia and distress during pregnancy and delivery. The company operates in the specialized obstetric medical device space with a portfolio spanning multiple sensing modalities.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES B

Total Funding

$5.6M

Open Jobs

About Raydiant Oximetry

AI assessmentNot Hiring

No open roles listed right now. Follow Raydiant Oximetry to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Fetal Pulse Oximetery

Fetal Hypoxia

N/A

Clinical Trials (1)

NCT07296419Dual System Study: Transvaginal Fetal Pulse Oximetry Measurement Systems

N/A

Help build intelligence for Raydiant Oximetry

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage Series B company with opportunity to shape clinical development strategy for multiple fetal monitoring programs with unmet clinical need
Focused specialty addresses a critical obstetric gap—real-time fetal oxygenation monitoring—offering clear clinical value proposition and regulatory pathway
Diverse pipeline with 7 programs across sensing technologies suggests platform approach and potential for multiple value inflection points

Watch Out For

Only 1 program (Fetal Oxygenation Measurements) has advanced to Phase 1; remaining 6 programs show no phase designation, indicating early preclinical/concept stage
No active job openings currently listed and incomplete company data (missing employee count, founding date, funding amount) suggests limited visibility and potential resource constraints
Pre-revenue status and Series B stage create uncertainty around cash runway, hiring velocity, and timeline to meaningful clinical or commercial milestones

Generated by Claude from Raydiant Oximetry's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ISS Device

Fetal Distress

N/A

Clinical Trials (1)

NCT04081584Trans-abdominal Fetal Pulse Oximetry: Tissue Light Scattering

N/A

Raydiant Oximetry Sensing System

Fetal Distress

N/A

Clinical Trials (1)

NCT04081623Trans-abdominal Fetal Pulse Oximetry: Signal Integrity

N/A